• Anthony Palumbo and Charles Goulding analyze Boston Scientific’s US$14.5 billion acquisition of Penumbra, showing how additive manufacturing can accelerate thrombectomy and neurovascular innovation through rapid device prototyping, micro-precision component development, production tooling, and the use of 3D printed vascular models for testing and physician training. • Introduction Boston Scientific announced on January 15, 2026, that it reached an agreement to acquire Penumbra, Inc. • for US$14.5 billion, a move that quickly drew attention across both the medical device sector and the 3D printing community. • The deal, Boston Scientific’s second-largest takeover, positions the company to re-enter the neurovascular space while further broadening its cardiovascular device portfolio. • Penumbra is a leading innovator in mechanical thrombectomy (clot-removing devices) and embolization technologies, categories that increasingly intersect with additive manufacturing (AM) through rapid prototyping, patient-specific models, and customized tooling. • This article provides a journalistic yet analytical look at the acquisition’s technological significance, with a specific focus on how 3D printing can support thrombectomy and vascular intervention development across the device lifecycle.

Article Summaries:

  • Anthony Palumbo and Charles Goulding analyze Boston Scientific’s US$14.5 billion acquisition of Penumbra, showing how additive manufacturing can accelerate thrombectomy and neurovascular innovation through rapid device prototyping, micro-precision component development, production tooling, and the use of 3D printed vascular models for testing and physician training. Introduction Boston Scientific announced on January 15, 2026, that it reached an agreement to acquire Penumbra, Inc. for US$14.5 billion, a move that quickly drew attention across both the medical device sector and the 3D printing

Sources: